Q-linea strengthens management team

UPPSALA, Sweden, 12 July, 2019 – Q-linea AB (publ) (Nasdaq Stockholm:QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today announced MD Tiziana Di Martino has been appointed the company’s Chief Medical Officer and will be part of Q-linea’s management team.

“I am pleased to welcome Tiziana Di Martino to the Q-linea-family. In her previous roles she has successfully managed clinical projects related to new product launches. Her experience will be a great benefit for Q-linea in our present position with our upcoming launches in Europe and the US.” said Jonas Jarvius, CEO of Q-linea.

Tiziana Di Martino has more than 16 years’ experience in clinical practice, research and medical affairs positions in the microbial diagnostic industry. Her latest position was Head of Clinical Development EMEA at Accelerate Diagnostics. Tiziana Di Martino is a Medical Doctor from Università Cattolica del Sacro Cuore in Rome, has a Master’s degree (MSc) in Toxicology from the University of Surrey and also holds an MBA from London Business School. Tiziana Di Martino will be part of Q-linea’s management team as of July 2019.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com,
+46 (0)70-323 77 60

Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0)70-600 15 20

About Q-linea

Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

The information was submitted for publication, through the agency of the contact persons set out above, at 09:00 CET on July 12, 2019.